Division of Neuropharmacological Drug Products

The author of the FDA memo revealing the decision to hide the existence of the clinical trials that had failed to find a difference between drug and placebo was Dr Paul Leber, Director of the FDA Division of Neuropharmacological Drug Products. Here is what he wrote about the labelling of Cipramil, which is referred to by its generic name, citalopram, in the document ... 

Division of Neuropharmacological Drug Products Food and Drug Administration Rockville, MD... 

Division of Neuropharmacological Drug Products, U.S. Food and Drug Administration Tacrine as a treatment for Alzheimer s disease an interim report from the FDA. N Engl J Med 324 349-352, 1991... 

The final label change was negotiated and approved under the authority of Paul Leber, Director of the Division of Neuropharmacological Drug Products, the division responsible for Halcion s original approval. In several ways, the label seems to fall far short of conclusions generated by both the literature and the division responsible for postmarketing surveillance. 

---